SELLAS Life Sciences has announced promising results from a major late-stage clinical trial of its experimental cancer vaccine, galinpepimut-S (GPS), showing a 41% reduction in the risk of death among certain patients with acute myeloid leukemia (AML). The results could mark an important step toward a new treatment option for people facing one of the most aggressive forms of blood cancer.
The company announced on November 17, 2026, that its pivotal Phase 3 REGAL trial successfully met its primary goal of improving overall survival. Following the positive findings, SELLAS plans to discuss the next regulatory steps with the U.S. Food and Drug Administration (FDA), with a potential Biologics License Application (BLA) submission targeted for the first half of 2027.
GPS Shows Significant Survival Improvement in Phase 3 Trial
The REGAL study compared galinpepimut-S with the best available treatment selected by investigators. According to the results announced by SELLAS, patients receiving GPS had a median overall survival of 24 months.
By comparison, patients in the control group had a median overall survival of 14.7 months. The treatment also demonstrated a 41% reduction in the risk of death, with a hazard ratio of 0.59.
The statistical results included a p-value of 0.035, meeting the trial’s predefined standard for statistical significance.
A total of 126 patients participated in the randomized study, with participants assigned to either GPS or the control treatment group.
Why the Results Matter for AML Patients
Acute myeloid leukemia is an aggressive blood and bone marrow cancer that affects the body’s ability to produce healthy blood cells. The disease can progress quickly, and treatment becomes particularly challenging when patients experience a relapse after initially responding to therapy.
The REGAL trial focused on a specific group of patients who had achieved a second or later remission following additional treatment but could not undergo an allogeneic stem cell transplant.
These patients often face limited treatment choices and a high risk of another relapse.
The survival improvement reported in the study is particularly important because it addresses a population with a significant unmet medical need. A treatment that can extend survival after remission could provide another option for patients who are unable to receive a transplant.
How SELLAS’ GPS Cancer Vaccine Works
Galinpepimut-S is an investigational immunotherapy designed to help the body’s immune system recognize and attack cancer cells.
The treatment targets Wilms’ Tumor 1 (WT1), a protein found in several types of cancer, including many cases of AML.
Rather than directly attacking cancer cells in the same way as traditional chemotherapy, GPS aims to stimulate an immune response against cells carrying the WT1 protein.
The goal is to help the immune system recognize remaining leukemia cells and reduce the possibility of disease returning.
The vaccine was originally discovered through research at Memorial Sloan Kettering Cancer Center and is licensed to SELLAS Life Sciences.
Safety Results Show Mostly Mild Side Effects
Alongside the survival findings, SELLAS reported that GPS was generally well tolerated during the trial.
The company said no new safety concerns were identified. Most treatment-related side effects were mild to moderate, with injection-site reactions among the most commonly reported problems.
The company also reported that the two treatment groups were balanced in important prognostic factors.
Detailed analysis of secondary endpoints and additional clinical data is still underway. SELLAS plans to present more comprehensive findings at a future major medical conference and submit the results for publication in a peer-reviewed medical journal.
FDA Discussions Could Begin Before 2027 Filing
Following the positive Phase 3 results, SELLAS intends to meet with the FDA to discuss a possible accelerated regulatory filing strategy.
The company is preparing for a Biologics License Application submission during the first half of 2027.
However, the results do not mean GPS has already received FDA approval. The regulatory agency must review the clinical evidence and determine whether the treatment meets the requirements for approval.
If the development and regulatory process moves forward successfully, GPS could eventually become an additional maintenance treatment option for selected AML patients who have limited alternatives.
FAQs
1. What is SELLAS’ GPS cancer vaccine?
GPS, also known as galinpepimut-S, is an experimental immunotherapy designed to help the immune system recognize and attack cancer cells carrying the WT1 protein.
2. How much did GPS reduce the risk of death?
The Phase 3 REGAL trial showed a 41% reduction in the risk of death compared with the best available treatment. Median overall survival was 24 months with GPS versus 14.7 months in the control group.
3. When could GPS receive FDA approval?
SELLAS plans to discuss the regulatory pathway with the FDA and is targeting a Biologics License Application submission in the first half of 2027. FDA approval has not yet been granted.


Pingback: FEMA Emergency Alert Test Today: Why TV and Radio Will Suddenly Sound an Alarm on November 17 - GyanDe.Com